| Active substance | sotorasib |
| Holder | Amgen |
| Status | closed |
| Indication | Treatment of adult patients with advanced non-small cell lung cancer (NSCLC) with KRAS G12C mutation and who have progressed after at least one prior line of systemic therapy |
| Public documents | Approbation |
| Information for the patient | |
| Informed consent | |
| Last update | 09/12/2022 |